Intravenous glucocorticoid treatment for Korean graves' ophthalmopathy patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ahn H.Y. | - |
dc.contributor.author | Lee J.K. | - |
dc.date.available | 2020-08-03T06:25:04Z | - |
dc.date.issued | 2020-06-15 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/42717 | - |
dc.description.abstract | Background: High-dose intravenous steroids are the first-line treatment for patients with moderate-to-severe and active Graves' ophthalmopathy (GO). We aimed to investigate the response rate of methylprednisolone (MPD) treatment among Korean patients with active moderate-to-severe GO and to identify predictive factors of treatment response. Methods: This is a retrospective observational study. We included 54 active moderate-to-severe GO patients treated with 4.5 g intravenous MPD over 12 weeks between November 2011 and November 2018. Response was defined as an improvement in at least two of five indicators (clinical activity score [CAS], soft-tissue involvement, exophthalmos, diplopia, and visual acuity) at immediate and 3 months after treatment completion. We examined predictive factors for response using logistic regression analysis. Results: Twenty-four (44.4%) and 22 (40.7%) patients showed response at immediate and 3 months after intravenous (IV) steroid treatment. Of the five ophthalmic parameters, all patients in the responsive group (100.0%) showed a decrease in CAS and 90.9% showed less soft tissue involvement after IV steroid treatment. Among variables, the sum of extraocular muscle width was positively (odds ratio [OR], 1.163; 95% confidence interval [CI], 0.973-1.389; P = 0.096) associated with treatment response. While, the OR of age was 0.918 (95% CI, 0.856-0.985; P = 0.017) and thyrotropin binding inhibitory immunoglobulin (TBII) was 0.921 (95% CI, 0.864-0.982; P = 0.012). Conclusion: In Korean active moderate-to-severe GO patients, intravenous steroid treatment is not as effective as previously reported. Parameters associated with CAS and soft-tissue involvement were found to be influenced by IV MPD treatment. Extraocular muscle enlargement, younger age and lower TBII are predictive factors for a good steroid treatment response. © 2020 The Korean Academy of Medical Sciences. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Korean Academy of Medical Science | - |
dc.title | Intravenous glucocorticoid treatment for Korean graves' ophthalmopathy patients | - |
dc.title.alternative | Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/JKMS.2020.35.E177 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.35, no.23, pp 1 - 9 | - |
dc.identifier.kciid | ART002594186 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000541750700002 | - |
dc.identifier.scopusid | 2-s2.0-85086335833 | - |
dc.citation.endPage | 9 | - |
dc.citation.number | 23 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 35 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Clinical activity score | - |
dc.subject.keywordAuthor | Glucocorticoids | - |
dc.subject.keywordAuthor | Graves' ophthalmopathy | - |
dc.subject.keywordAuthor | Response rate | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | ORBITOPATHY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | PREDICT | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.